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Abstract 
The extent to which cells in normal tissues accumulate mutations throughout life is poorly 
understood. Some mutant cells expand into clones that can be detected by genome sequencing. 
We mapped mutant clones in normal esophageal epithelium from nine donors (age range 20 to 
75 years). Somatic mutations accumulated with age and were mainly caused by intrinsic 
mutational processes. We found strong positive selection of clones carrying mutations in 14 
cancer genes, with tens to hundreds of clones per square centimeter. In middle-aged and elderly 
donors, clones with cancer-associated mutations covered much of the epithelium, with 
NOTCH1 and TP53 mutations affecting 12 to 80% and 2 to 37% of cells, respectively. 
Unexpectedly, the prevalence of NOTCH1 mutations in normal esophagus was several times 
higher than in esophageal cancers. These findings have implications for our understanding of 
cancer and ageing. 
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Main Text: 
 
 
Somatic mutations occur in healthy cells throughout life (1-3). Most of these mutations do not 
alter cell behaviour and accumulate passively (4). Occasionally, however, a key gene is altered 
in a way that provides mutant cells with a competitive advantage, leading to the formation of 
persistent mutant clones. Such clones are thought to be the origin of cancer and have also been 
linked to other diseases (5, 6). Despite its importance, understanding the extent of somatic 
mutation in normal tissues has been challenging due to the difficulties of identifying mutations 
present in small numbers of cells. 
 
The most highly mutated normal tissue reported to date is sun-exposed human skin. Deep 
targeted sequencing of sun-exposed skin from four middle-aged individuals revealed large 
numbers of mutant clones under positive selection, with around a quarter of skin cells carrying 
cancer-driving mutations (7). Since most mutations were caused by ultraviolet light, it is 
unclear whether aged sun-exposed skin represents a special case due to a lifetime exposure to 
a powerful mutagen. This question motivated us to investigate the mutational landscape of 
esophageal epithelium, a tissue with a similar structure but a very different exposure to 
mutagens. Like the skin, esophageal epithelium consists of layers of keratinocytes. Cells are 
shed from the surface throughout life and are replaced by proliferation. In addition, both the 
skin and the upper- and mid-esophagus develop squamous cell cancers. 
 
We performed ultra-deep targeted sequencing of 844 small samples of normal esophageal 
epithelium from nine deceased organ transplant donors, ranging from 20 to 75 years of age 
(Table S1). None of the donors had a known history of esophageal or other chronic disease and 
none was taking prescription medication for gastroesophageal reflux. Four of the nine donors 
had a history of cigarette smoking. Upper- and mid-esophageal epithelium was separated from 
the underlying stroma and cut into a contiguous grid of 2mm2 samples, allowing us to map 
clones that spanned multiple samples (Methods S1). Each sample was examined under a 
dissecting microscope and no lesions were seen. Histology and wholemount confocal imaging 
of adjacent tissue were also normal (Fig. S1, S2). Deep targeted sequencing of 74 cancer genes 
was performed on each sample to a median on-target coverage after duplicate removal of 870x 
(Methods S2). 21 samples that were found to be dominated by large clones from the targeted 
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sequencing data were also whole-genome sequenced to a median coverage of 37x. This 
captures the state of the genome of the cell whose progeny subsequently colonized the sample. 
 
Detection of mutations in normal esophagus 
 
To detect mutations present in only a small fraction of each sample from deep-targeted 
sequencing data we used the ShearwaterML algorithm (7, 8). This algorithm uses the observed 
error rates per site from a large collection of normal samples to build a site-specific error model 
for every type of change in every targeted site (Methods S3, Fig. S3). In this dataset, we 
identified 8,919 somatic coding mutations across 844 samples from all donors (total area 
~17cm2). Of these, 6,935 were considered independent events after merging mutations shared 
by nearby samples into single clones (Methods S3.3) (Table S2). Most sites in the genome 
display error rates below 1e-4 errors per base, which enables accurate identification of 
mutations at low allele frequencies (Methods S3.2, Fig. S3-S4). The median allele frequency 
of the mutations detected by ShearwaterML was 1.6%, with a third of all mutations below 1% 
(Fig. S3). Since the fraction of sequencing reads that carry a mutation is a function of the 
fraction of mutant cells within a sample and of the local copy number, we can integrate allele 
frequencies and sample areas to obtain approximate estimates of the sizes of detectable mutant 
clones in normal esophagus, which ranged from 0.01 to over 8 mm2 (Methods S5). 
 
The number of mutations identified per sample and their allele frequencies varied markedly 
across individuals, with both the number of detectable mutations and the sizes of mutant clones 
roughly increasing with donor age (Fig. 1A-B). To better understand the passive rate of 
accumulation of mutations in healthy esophagus, we can estimate the mean number of 
mutations per cell in each individual by integrating allele frequencies (Methods S5) (7). These 
are conservative lower-bound estimates as they are limited to mutations present in detectable 
clones. On average, healthy cells in the esophageal epithelium carry at least several hundred 
mutations per cell in people in their twenties, rising to over 2,000 mutations per cell late in life 
(Fig. 1C). Similar estimates were obtained from the whole-genome sequencing data (Methods 
S5.1). These estimates of the mutation rate in normal esophagus are broadly comparable to the 
mutation rates reported in human stem cells of the colon, small intestine and liver based on 
sequencing of clonal organoids (9). 
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Widespread positive selection driving clonal growth 
 
In middle-aged individuals, the number of mutations per cell is approximately ten times lower 
in normal esophagus than in sun-exposed skin (7), a difference partially due to the high degree 
of UV-damage sustained by the skin. Given this, we anticipated that the frequency of cancer-
driver mutations in esophagus would be much lower than that in skin. Unexpectedly, however, 
analysis of the frequency and size of mutant clones revealed a higher density of cancer-
associated mutations in normal esophagus than in sun-exposed skin, suggesting that there is 
stronger positive selection of clones with mutations in cancer-associated genes. 
 
To formally quantify the extent of selection driving clonal expansions in normal esophagus, 
we estimated the ratio of non-synonymous (dN) to synonymous (dS) mutation rates (dN/dS) 
across genes, which is a widely-used measure of selection. We used dNdScv, an 
implementation of dN/dS for somatic data that controls for trinucleotide mutational signatures, 
sequence composition and variable mutation rates across genes (4) (Methods S6). This method 
has been shown to reliably identify genes under positive selection in cancer and normal tissues 
(4, 7). In the context of this experiment, dN/dS ratios reveal how much more (or less) likely it 
is for a non-synonymous mutation to reach a detectable clone size compared to a synonymous 
mutation (Methods S6.2). 
 
This analysis revealed strong evidence of selection driving clonal expansions in normal 
esophagus. At the gene-level, we detected significant positive selection in 14 of the genes that 
we sequenced (Fig. 2A-D) (Table S3). This means that mutation of these genes confers a 
competitive advantage on mutant cells relative to neighboring cells. Sorted by mutation 
frequency, the list comprises NOTCH1, TP53, NOTCH2, FAT1, NOTCH3, ARID1A, KMT2D, 
CUL3, AJUBA, PIK3CA, ARID2, TP63, NFE2L2 and CCND1. Interestingly, the five most 
frequently mutated genes in normal esophagus also dominated the mutational landscape in sun-
exposed skin. Many of the positively selected genes play a role in keratinocyte differentiation 
through NOTCH signaling e.g. NOTCH1, NOTCH3, and TP53 (10-13); through redox cellular 
stress e.g. NFE2L2, TP63 and CUL3 (14-17) or through epigenetic regulation e.g. KMT2D 
(18). Tilting cell fate balance away from differentiation toward proliferation may confer a 
competitive advantage to mutant cells in normal esophageal epithelium (19). 
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At least 11 of the 14 genes found under positive selection in normal esophagus are canonical 
drivers of esophageal squamous cell carcinomas (ESCC) (Methods S6.5) (20-22). Their 
presence in normal epithelium suggests that they might act as early ESCC drivers, leading to 
the expansion of persisting clones that could undergo further mutation and malignant 
transformation. The landscape of selection in normal squamous epithelium of the esophagus 
more closely resembles that of ESCCs than esophageal adenocarcinomas (EACs) (21), 
consistent with the fact that ESCCs typically develop from the squamous epithelium of upper- 
and mid-esophagus, while EACs evolve from epithelium close to the stomach junction and are 
associated with Barrett’s metaplasia. 
 
Colonization of the epithelium by NOTCH1-mutant clones 
 
One unexpected observation was the very high prevalence of NOTCH1 mutations in normal 
esophagus (Fig. 2A-C). Across the nine donors, we detected 2,055 coding mutations in 
NOTCH1, of which over 98% were non-synonymous, with an average of ~120 different 
NOTCH1 mutations per cm2 of normal esophagus (Fig. 2A). NOTCH1 acts as an oncogene in 
different leukemias but has a mutation pattern consistent with a tumor suppressor gene in 
squamous carcinomas (SCCs) of the skin, head and neck, esophagus and lung (23). As in SCCs, 
mutations in NOTCH1 in normal esophagus were enriched for truncating mutations 
(dN/dS>50), including stop-gains, essential splice site mutations and indels (Fig. 2B). Missense 
mutations were also frequent in NOTCH1, and they were concentrated in five of the 36 
extracellular epidermal growth factor (EGF) repeat domains, EGF8-12 (Fig. 2E). These EGF 
repeats contain the binding domains for the Notch1 ligands Jagged and Delta. The most 
recurrent codon alterations occurred at sites predicted to affect structural residues (calcium-
binding motifs, cysteine residues, interdomain packing) or the contact surface with Notch1 
ligands (Fig. 2F) (Supplementary Text) (23, 24). The large number of positively-selected 
NOTCH1 mutations provides structural and functional insights into this key regulatory protein. 
 
Integrating the allele fractions of the mutations and allowing for the possibility that mutations 
may affect one or two alleles per cell, we can estimate the fraction of mutant cells in a tissue 
for any given gene (Methods S5.3). On average across the nine donors, 25 to 42% of the cells 
in normal esophagus harbored NOTCH1 mutations (Fig. 2C). There was a large increase in the 
frequency of NOTCH1 mutant clones with age. Approximately 30 to 80% of normal esophagus 
was NOTCH1-mutant in five of the six middle-aged or elderly individuals compared to 1 to 
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6% in the three individuals under 40 years of age (Fig. 2G). This observation is consistent with 
data from experimental mouse models showing that transgenic inhibition of Notch signaling in 
a small fraction of cells confers clonal advantage and enables these clones to colonize the 
normal esophageal epithelium (19, 25). 
 
This observation has potentially important implications. The NOTCH1 gene has been widely 
assumed to be a driver in ESCCs because it is mutated in ~10% of tumors (21, 26) (Fig. 2D,G). 
The observation that, in middle-aged individuals, NOTCH1 is typically mutated in 30 to 80% 
of the normal esophageal epithelium suggests that NOTCH1 mutations may be less frequent in 
cancers than in the background of normal tissue from which the cancers develop. This raises 
questions about the role of NOTCH1 in the development of ESCCs. 
 
The case of NOTCH1 contrasts with that of TP53 (Fig. 2G), which is mutated in over 90% of 
ESCCs but in a minority of cells in the normal esophageal epithelium. TP53 is the second most 
frequently mutated gene in normal esophagus, with ~35 mutations per square centimeter and 
strong positive selection for both truncating and missense mutations (dN/dS ratios ~150 and 
~50, respectively; Fig. 2A,B). As in cancer genomes, the missense mutations mostly affect the 
central DNA-binding domain (Fig. 2E). Across the nine donors, 5 to 10% of the epithelium 
carried a TP53 mutation, a fraction that appeared to increase with age, with the oldest donor 
having TP53 mutations in 20 to 35% of cells (Fig. 2G).  
 
In summary, we found an unexpectedly high density of driver mutations in normal esophagus 
and positive selection acting on most of the main drivers of ESCC. Combining the 74 genes 
studied, global dN/dS ratios for missense and protein-truncating (nonsense and essential splice 
site) mutations were around 2.2 and 8.6, respectively, with the enrichment of non-synonymous 
mutations increasing rapidly with clone size (Fig. 2H, Fig. S5B). This suggests that 
approximately 55% of all missense mutations and 88% of all truncating mutations identified 
in this dataset were actively driven to detectable clone sizes by positive clonal selection. 
Overall, using dN/dS ratios, and considering substitutions and indels in the 14 genes under 
significant selection, we estimate that there are 3,915 (CI95%: 3,829-3,988) positively-selected 
driver mutations in the ~17 cm2 of normal esophageal epithelium sequenced in this study, of 
which 52% are in genes other than NOTCH1 (Methods S6.3). This number is comparable to 
the yield of driver mutations obtained from sequencing over 1,000 cancer genomes (4). 
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Variation of the mutational and selective landscape across donors 
 
The patterns of somatic evolution varied greatly across the nine individuals in this study 
showed large differences in mutation density, clone sizes and overall driver frequency (Fig. 3). 
Age is by far the strongest risk factor in ESCC, with cancer incidence rising near-geometrically 
with age (27, 28). We used mixed effect regression models to evaluate the association between 
the mutation landscape and age, while controlling for other risk factors such as gender and 
smoking status (Methods S7). Despite the modest cohort size, this analysis revealed a 
significant increase in the number of mutations per sample (P-value=0.009) and clone sizes (P-
value=0.027) with age. This is consistent with the significant increase in mutation burden with 
age described in Fig. 1C by standard linear regression (P-value=0.0068, R2=0.67). We also 
noted that the two heavy smokers in the cohort appear to have a higher number of mutations 
than expected for their age (Fig. 1A, Fig. 3, Methods S7). However, larger cohorts will be 
needed to reliably study the impact of behavioral risk factors on the mutational landscape in 
the esophagus. 
 
Despite the dominant effect of age, there are unexplained differences across individuals, 
including differences in the strength of selection on different genes across individuals, as 
suggested by the different colored clones in Fig. 3. To formally quantify differences in selection 
pressure per gene across donors, while removing the effect of variable mutation rates and 
signatures across individuals, we used an extension of dNdScv that compares two dN/dS ratios 
(Methods S6.4). This confirmed that there are significant differences in the driver landscape 
across donors (Fig. S5C-E). For example, across individuals, NOTCH1 is mutated 5 times more 
frequently than NOTCH3. Yet, in one donor, we detected nearly the same number of mutations 
in NOTCH1 and NOTCH3 (Fig. S5D, q-value=5e-13, Likelihood-Ratio Test). Similarly, the 
oldest donor showed a 2-fold relative enrichment in TP53 mutations compared to other 
individuals (q-value<1e-15, Likelihood-Ratio Test; Fig. S5E), consistent with the observation 
that 20 to 37% of normal esophageal epithelium was TP53 mutant in this donor (Fig. 2G). It is 
unclear whether the variation in the driver landscape across donors reflects differences in 
exposure to environmental factors, the genetic background of each individual or both. 
Nevertheless, differences in mutation rates, clone sizes and driver preferences may have 
implications for understanding inter-individual variation in cancer risk. 
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Given the large increase in driver mutant clones with age, many clones are expected to acquire 
more than one driver mutation over the course of a lifetime. Although the small clone sizes 
limit our ability to determine which mutations within a sample occur in the same cells, 25 
samples had sufficiently large clones for us to confidently group mutations (Methods S5.5) 
(Fig. 4A and Fig. S6). Most cases (14/25) were examples of NOTCH1 bi-allelic inactivation 
by two mutations. We also observed examples of clones carrying mutations in NOTCH1 and 
FAT1, NOTCH1 and NOTCH3, and PIK3CA and NOTCH3. In the oldest donor (aged 72-75 
years), whose samples showed an enrichment of TP53 mutations, we found a large clone, 
measuring over 4 mm2, with a founder heterozygous TP53 mutation and three separate 
subclones each carrying a second TP53 mutation (Fig. 4A). In a large clone extending over six 
samples and measuring over 8.5 mm2, we were able to integrate whole-genome data and spatial 
information to reconstruct its phylogenetic history (Methods S5.6). The tree shows that the 
ancestor cell underwent a large clonal expansion after losing both copies of NOTCH1, followed 
by branching evolution with two subclones dominating spatially distinct areas (Fig. 4B).  
 
The whole-genome mutational landscape in normal esophagus 
 
To better understand the contribution of different mutational processes and the extent of 
structural variation in normal esophagus, we performed whole-genome sequencing of 21 
samples dominated by a major clone. Across all donors, C>T/G>A mutations dominate the 
spectra with a clear excess of mutations at CpG dinucleotides (Fig. 4C,D; Fig. S7). These 
changes result from the deamination of 5-methylcytosine into thymine, and are believed to 
occur spontaneously throughout life (29, 30). Signature analysis revealed that the pattern of 
mutations largely resembles a combination of COSMIC mutational signatures 1 and 5 (30) 
(Methods S4, Fig. S7,8). Both signatures have been shown to dominate the accumulation of 
mutations in normal tissues such as colon, small intestine and liver during life (9). 
 
In addition, we observed two other mutational processes. There was a considerable rate of 
C>A/G>T changes with a modest but significant transcription-strand bias. Multiple 
mechanisms can lead to these types of changes, including smoking. Although four of the nine 
individuals were smokers, we did not observe a clear signature of tobacco-induced mutations 
(COSMIC signature 4) (Methods S4). We also observed considerable variation in T>C changes 
across the 21 whole-genomes, with a strong transcription strand asymmetry (Fig. 4D, Fig. 
S7,8). Stratification of the mutation spectra by gene expression level revealed that highly 
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transcribed genes are targets of a process of transcription-coupled mutagenesis that induces 
T>C changes preferentially at ApT sites in the transcribed strand, a phenomenon previously 
described in liver cancers (31) (related to COSMIC signature 16) (Fig. 4D, Fig. S8).  
 
Overall most mutations seem to be generated by intrinsic mutational processes associated with 
age or transcription (30, 31), without clear evidence of external mutagenic processes. 
Interestingly, we found no evidence of COSMIC signatures 2 and 13 in the targeted or the 
whole-genome data. These signatures are believed to be caused by APOBEC cytidine 
deaminases and contribute large numbers of mutations in esophageal cancers (20, 21, 32). This 
partially explains the observation that the mutation burden in normal esophagus is 
approximately an order of magnitude lower than the median mutation burden of ESCC and 
EAC cancers (Fig. 4E). The rarity of APOBEC mutagenesis in normal esophagus may suggest 
that this is acquired later in the evolution of ESCC or that ESCCs are more likely to evolve 
from rare clones displaying APOBEC mutagenesis. 
 
Esophageal cancers are characterized by large numbers of copy number changes and structural 
rearrangements (21, 33). To explore the extent of copy number changes in normal esophagus, 
we first analyzed the deep targeted sequencing data. We used a copy number detection 
algorithm designed to identify low-frequency subclonal loss of heterozygosity (LOH) on 
targeted data, exploiting the statistical phasing of heterozygous SNPs to detect small allelic 
imbalances (7) (Methods S3.4). NOTCH1 loss was the most frequent copy number change 
identified, although caution must be exercised because statistical power varies across genes 
and donors. NOTCH1 LOH was detected in nearly 30% of all samples (Fig. 4F) and in virtually 
all of the samples with a single high-frequency NOTCH1 mutation, confirming that loss of 
NOTCH1 is typically bi-allelic. PTCH1 sits on the same arm of chromosome 9 as NOTCH1 
and is often lost together with NOTCH1. We also detected less frequent but recurrent whole-
chromosome 3 gains, which lead to the duplication of PIK3CA/SOX2/TP63, an event observed 
in approximately half of ESCCs (21) (Fig. 4F). Several instances of TP53 LOH were also 
detected, largely concentrated in the oldest donor. 
 
Copy number analysis of the 21 whole-genomes confirmed that segmental loss of NOTCH1 is 
typically mediated by copy-neutral LOH without detectable rearrangements (Fig. 4G, Fig. S9, 
Methods S3.5.2, Table S4). Such events may be generated by mitotic homologous 
recombination. Events varied in size, from whole-arm losses to focal events (Fig. 4G, Fig. 
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S9,10). With the exception of copy-neutral LOH events in NOTCH1 and an instance of 
chromosome 3 gain, the 21 genomes appeared largely diploid, without evidence of other copy 
number changes that may be expected to accumulate by chance over time (Fig. 4G, Fig. S9, 
Methods S3.5.2, Table S4). The rarity of copy number changes in large clones, none of which 
had TP53 mutations, suggests that the background rate of copy number changes is low in 
normal cells of the esophagus or that such changes are negatively selected. Either way, this 
represents a major difference between normal esophageal cells and ESCCs, suggesting that 
structural changes may occur late in the evolution of esophageal cancers (33). 
 
Discussion 
 
These data have unveiled a hidden world of somatic mutation and clonal competition in normal 
esophagus. We have detected thousands of mutations per cell, hundreds of positively selected 
clones per square centimeter, and clones with cancer-associated mutations colonizing most of 
the esophageal epithelium with age, all without grossly detectable changes in histology. 
 
The higher frequency of cancer-associated mutations in normal esophagus than in sun-exposed 
skin is unexpected, particularly given the lower mutation rate in the esophagus. Although we 
found most of the common drivers of ESCC already under selection in normal esophageal 
epithelium, key differences remain between the genomes of cells in mutant clones in aging 
normal epithelium and cancer cells. These include a mutation burden approximately ten times 
lower than that in many ESCCs, no evidence of APOBEC mutagenesis and an apparent lack 
of chromosomal instability. Further, although clones carrying cancer-driver mutations are 
widespread, the average number of driver mutations per cell in normal esophagus is much 
lower than that in cancer cells (Fig. 2C), a result consistent with the multi-stage theory of 
carcinogenesis (27, 28, 34). Larger scale genomic studies of normal tissues in healthy 
individuals and of premalignant lesions of different grades will help refine our understanding 
of the transition from normal to cancer (3, 28, 33, 35). 
 
An unexpected observation is the high frequency of NOTCH1 mutation in aged normal 
esophagus compared to ESCCs. This suggests that ESCCs are more likely to evolve from cells 
in the epithelium without NOTCH1 mutations. In contrast, TP53 mutations, which are several-
fold less frequent than NOTCH1 mutations, are almost ubiquitous in ESCCs, suggesting that 
cancers arise from the small fraction of TP53 mutant cells. Cancer risk may therefore vary 
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across the aging epithelium depending on the colonizing mutations present. Interventions that 
decrease the proportion of mutations at a higher risk of transformation in normal epithelium 
may thus be beneficial. 
 
We note that, even if they do not contribute to carcinogenesis, drivers of benign clonal 
expansions could still appear as recurrently mutated genes in cancer genomes owing to their 
high mutation frequency in the normal cells from which tumors evolve. Better understanding 
of the mutational landscape in normal tissues may thus help refine current catalogs of cancer-
driver genes, with important implications for early diagnosis and targeted therapy. 
 
Positive selection of mutant clones has now been observed during normal aging in blood, sun-
exposed skin and esophageal epithelium (7, 36). This opens the theoretical possibility of clonal 
selection across tissues as a contributing factor to tissue and organismal aging (4, 37, 38). 
Somatic mutation has long been recognized as a possible factor contributing to aging, with 
mutations and other forms of damage deleterious to the carrying cells passively accumulating 
during life and progressively reducing cellular fitness (39). Widespread positive selection of 
mutant clones may be an additional contributory factor in ageing as it can greatly accelerate 
the accumulation of functional mutations and altered phenotypes. Throughout life, somatic 
mutations increasing cellular fitness can spread and even dominate tissues, independently of 
their cost to the organism. If the selected mutations negatively impact tissue function, the 
physiological integrity of the organism will decline, a hallmark of the aging process. 
 
This study emphasizes how little we know about somatic evolution within normal tissues, a 
fundamental process that is likely to take place to varying degrees in every tissue of every 
species. Better understanding of the extent of somatic mutation and selection across tissues, in 
health and disease promises to provide insights into the origins of cancer and aging. 
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Main text figures 
 
 
 
 
Fig. 1. Detection of somatic mutations in normal esophagus. (A) Number of mutations 
detected per sample across the 844 samples from the 9 transplant donors (sorted by age). Donor 
age is shown as 4-year bins to increase sample anonymity. (B) Variant allele fraction (VAF) 
of the mutations detected in the youngest and oldest donor, colored by mutation type. The VAF 
is the fraction of sequencing reads reporting a mutation within a sample. (C) Scatter plot of 
donor age and the estimated mean mutation burden per cell for each donor. The fitted line, R-
square value and P-value were obtained by linear regression. 
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Fig. 2. Widespread positive selection of cancer-associated mutations in normal esophagus. 
(A) Number of mutations detected in each of the 14 genes found under positive selection. (B) 
Observed-to-expected ratios for missense substitutions, truncating (nonsense and essential 
splice site) substitutions and indels. Observed-to-expected ratios for substitutions are dN/dS 
ratios. Only ratios with P<0.05 are shown. (C) Estimated percentage of cells carrying a 
mutation in each gene (Methods S5.3). (D) Percentage of ESCCs with a non-synonymous 
substitution or an indel in each gene. Error bars depict 95% Poisson confidence intervals. (E) 
Distribution of mutations within TP53 and NOTCH1 in normal esophagus (above the gene 
domains diagram) and in SCC cancers from TCGA (below). EGF8-12 region is boxed. (F) 
Consequences of NOTCH1 missense mutations. (Top panel) Most affect structural residues in 
EGF domains (shown in stick form, PDB 2VJ3): calcium-binding consensus residues (red), 
hydrophobic interdomain packing residues (teal), cysteine residues which form disulphide 
bonds (yellow), conserved glycines (black). Calcium ions shown as red spheres. (Bottom 
panel) Other residues affected by missense mutations (≥4 per residue) in the EGF8-12 region 
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are shown in space filling representation. Many are predicted to disrupt the Notch 
receptor/ligand binding interface (shown in deep blue and labelled with residue number), while 
others are distal (colored wheat) (PDB 5UK5). (G) Estimated percentage of mutant epithelium 
per donor compared to ESCC mutation frequency. (H) dN/dS values estimated from all 74 
target genes together in normal esophagus and sun-exposed skin (7). 
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Fig. 3. Variation of the mutational landscape across the 9 donors. Representative 
patchwork plots from each donor. Each panel is a schematic representation of the mutant clones 
in an average 1 cm2 of normal esophageal epithelium from each donor. To generate each figure, 
a number of samples from the donor are randomly selected to amount to 1 cm2 of tissue and all 
clones detected are represented as circles randomly distributed in space. The density and size 
of the clones are inferred from the sequencing data and the nesting of clones and subclones is 
inferred from the data when possible and randomly allocated otherwise (Methods S5.4). 
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Fig. 4. Phylogenetic and mutational patterns in normal esophagus. (A) Representation of 
mutations co-occurring in the same clones using the pigeonhole principle (see Supplementary 
material 5.5). (B) Phylogenetic reconstruction of the evolution of a large clone overlapping six 
samples using whole-genome sequencing data and spatial information. A small heatmap of the 
six affected samples is shown next to each node in the tree, depicting the mean VAF of the 
mutations in each node. (C) Number of substitutions per mutation type as mapped to the coding 
(untranscribed) strand from all donors. P-values reflect transcription strand asymmetry (exact 
Poisson test). (D) 96-mutation-class barplot depicting the number of mutations in each of the 
possible 96 trinucleotides (strand independent). The top panel shows the whole-genome plot 
aggregating all 21 whole-genomes. The bottom panel shows the spectrum for mutations 
occurring in the transcribed region of the top 20% most highly expressed genes. (E) Mutation 
burden in normal esophagus and in ESCC and EAC tumors (every point corresponds to a donor, 
sorted by mutation burden). (F) Number of copy number events detected in each gene across 
the 844 samples using the targeted data. (G) Representative LogR and B-allele frequency 
(BAF) scatter plots for heterozygous SNPs from whole genome data showing a copy-neutral 
LOH event affecting NOTCH1 (sample PD30273bg shown). 
 
